Evidence map›Paper›PMID 32291904›Full record

ArticleThoracic cancer2020

First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.

Kosuke Hamai, Hiroki Tanahashi, Sayaka Ueno, Hanae Konishi, Mirai Matsumura, Akio Nomura, Kanako Nakamoto, Shoko Isoyama, Takuya Tanimoto, Hiroyasu Shoda and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Frontiers in oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kosuke HamaiDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.ORCID 0000-0002-8654-5532
Hiroki TanahashiDepartment of Internal and Molecular Medicine, Hiroshima University, Hiroshima, Japan.
Sayaka UenoDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Hanae KonishiDepartment of Respiratory Medicine, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Mirai MatsumuraDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Akio NomuraDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Kanako NakamotoDepartment of Respiratory Medicine, Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.
Shoko IsoyamaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Takuya TanimotoDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Hiroyasu ShodaDepartment of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Nobuhisa IshikawaDepartment of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Hiroshima Prefectural Hospital · JPHiroshima City Asa Citizens Hospital · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 90-year-old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT-guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death-ligand 1 (PD-L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first-line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD-L1 are very rare.

Indexed as

MutationAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellErbB ReceptorsFatal OutcomeFemaleHumansLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCD274 protein, humanEGFR protein, humanErbB ReceptorspembrolizumabEpidermal growth factor receptor (EGFR) mutationpembrolizumabprogrammed death-ligand 1 (PD-L1)squamous cell lung cancer

Identifiers

PMID32291904
PMCPMC7262880
OpenAlexW3016003456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.